2020
DOI: 10.21203/rs.3.rs-24915/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Targeting fibroblast activation protein (FAP): Next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

Abstract: Background Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other group… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 37 publications
(48 reference statements)
0
1
0
Order By: Relevance
“…The new class of FAPi-radiopharmaceuticals utilizes a squaric acid (SA) motif as part of the structure connecting the inhibitor moiety UAMC 1110 with various chelators such as DOTA and DATA, yielding precursors of type DOTA.SA.FAPi or DATA 5m .SA.FAPi. All compounds are of low nanomolar binding affinity to FAP and excellent selectivity towards other proteases [3]. Focal nodular hyperplasia (FNH) is the second most common benign liver tumor.…”
Section: Introductionmentioning
confidence: 99%
“…The new class of FAPi-radiopharmaceuticals utilizes a squaric acid (SA) motif as part of the structure connecting the inhibitor moiety UAMC 1110 with various chelators such as DOTA and DATA, yielding precursors of type DOTA.SA.FAPi or DATA 5m .SA.FAPi. All compounds are of low nanomolar binding affinity to FAP and excellent selectivity towards other proteases [3]. Focal nodular hyperplasia (FNH) is the second most common benign liver tumor.…”
Section: Introductionmentioning
confidence: 99%